Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size

Series A

AltPep unpacks $23.1m round
University of Washington spinout AltPep will use the money to advance work on its lead asset that targets Alzheimer’s disease.
Atalanta attains series A
Atalanta Therapeutics has launched out of UMass with $110m in combined series A and partnership funding to develop therapies for neurodegenerative diseases.
Lexeo stacks up $85m
Weill Cornell Medicine‘s monogenic diseases therapy developer Lexeo Therapeutics has made its public debut with $85m in series A financing.
Daily deal net: January 8, 2021
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
IconOVir Bio conducts $77m series A
The oncolytic virus therapy-based cancer drug developer is based on research at Salk Institute and has raised $77m in its series A round.
Deal net: December 18 to 31, 2020
Today’s deal net round ups the smaller investments from across the university innovation ecosystem that have occurred over the holiday period.
Magnax pushes ignition on $19.5m round
Magnax raised the cash from investors including automotive parts firm Hirschvogel Automotive with a view of broadening R&D and entering new markets with its EV motor technology.
Neomorph bonds $109m
Based on inventions from Harvard and Dana-Farber Cancer Institute, Neomorph was launched earlier this year with the support of Deerfield Management.

Other News

Daily deal net: December 18, 2020
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Atsena actions $55m series A
University of Florida has backed a second round for Atsena, a vision loss therapy developer exploiting inventions the institution had originally licensed to Sanofi.
Exo Therapeutics executes $25m series A
The exosite drug developer has launched publicly to advance research from Harvard University and Salk Institute for Biological Studies.
Faze Medicines fades in with $81m
The neurodegenerative disorder drug developer has emerged from stealth to commercialise Howard Hughes Medical Institute research.
InnoSkel sets out with $24.3m
Spun out of University of Côte d’Azur and Inserm, InnoSkel expects to fund clinical work to address a form of skeletal dysplasia that causes dwarfism.
Oxford pops into PepGen’s $45m series A
University of Oxford joined Oxford Sciences Innovation to back neuromuscular disease therapy spinout PepGen, which will move its base to the US.

Editor's Picks

Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Big deal: NMD flexes series A muscles
Aarhus University spinout NMD Pharma, which focuses on therapies for neuromuscular conditions, has attracted the support of several corporates for its $47m series A round.
Immunocore smashes European biotech records
Immunotherapy firm Immunocore, which started life at Oxford University, raises the largest biotech round in European history.
Sphere Fluidics circles $2.5m
test reg

Login